NCT05645900View on ClinicalTrials.gov

A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months

PHASE3CompletedINTERVENTIONAL
Enrollment

2,772

Participants

Timeline

Start Date

February 6, 2023

Primary Completion Date

October 13, 2023

Study Completion Date

October 13, 2023

Conditions
Influenza
Interventions
BIOLOGICAL

Quadrivalent influenza virus subunit vaccine

This vaccine（0.5ml） is produced by Ab\&b Biotechnology Co., Ltd.JS。Subjects will receive two doses of quadrivalent influenza virus subunit vaccine administered 28 days apart by intramuscular injection

BIOLOGICAL

Quadrivalent influenza virus subunit vaccine

This vaccine（0.25ml） is produced by Ab\&b Biotechnology Co., Ltd.JS。Subjects will receive two doses of quadrivalent influenza virus subunit vaccine administered 28 days apart by intramuscular injection

BIOLOGICAL

Quadrivalent split influenza virus vaccine

This vaccine（0.25ml） is produced by HUALAN BIO。Subjects will receive two doses of quadrivalent split influenza virus vaccine administered 28 days apart by intramuscular injection

Trial Locations (1)

225300

Ab&b Biotechnology Co., Ltd.JS, Taizhou

All Listed Sponsors
collaborator

Henan Center for Disease Control and Prevention

OTHER_GOV

lead

Ab&B Bio-tech Co., Ltd.JS

OTHER